Skip to main content

Table 3 EVs as diagnostic biomarkers for CCA

From: The role of extracellular vesicles in cholangiocarcinoma

Biomarkers AUC Sensitivity Specificity Reference
CCA vs. PSC BBO [98]
 Bile: miR-based panel Null 67% 96%  
CCA vs. BBD [103]
 Bile: miR-30d-5p 0.730 81.1 60.5  
  miR-92a-3p 0.652 65.7 66.7  
 Serum: CA19-9 0.675 70.3 64.6  
  CEA 0.603 64.9 60.4  
CCA vs. BBO [99]
 Bile lncRNAs: ENST00000588480.1 and ENST00000517758.1 0.709 82.9 58.9  
 Serum: CA19-9 0.729 74.3 71.4  
CCA: TNMs I, II vs. TNMs III, IV [105]
 Serum: HSP90B-s255 0.936 87.27 97.62  
MCBDS vs. NMCBDS [42]
 Concentration of EVs 1.000 Null Null  
 Serum: CA19-9 0.733 Null Null  
CCA vs. HC [82]
 Serum: miR-200c-3p 0.930 Null Null  
 Serum: CA19-9 0.780 Null Null  
CCA vs. PSC [104]
 FIBG 0.796 Null Null  
 A1AG1 0.794 Null Null  
 S10A8 0.759 Null Null  
 Serum: CA19-9 0.819 Null Null  
CCA vs. HC
 AMPN 0.878 Null Null  
 VNN1 0.876 Null Null  
 PIGR 0.844 Null Null  
 Serum: CA19-9 0.907 Null Null